Evaluating intermittent dosing of aspirin for colorectal cancer prevention
Ended Awarded Last action
- Contract number
- HHSN26100009
- Awardee
-
Northwestern University UEI KG76WYENL5K1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,057,269
Award facts
- Contract value 100% obligated
- $1,057,268.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Chicago, IL 60611, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$410,747 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $226,821 | |
| Exercise an Option | $600,700 | |
| Exercise an Option | $215,747 | |
| Other Administrative Action | $107,957 | |
| Original award | $316,791 |
About this award
This federal contract award from the National Cancer Institute (NCI), part of the Department of Health and Human Services, is for a clinical research study to evaluate the efficacy of intermittent dosing of aspirin for colorectal cancer prevention. The prime contractor is Northwestern University, a private research university, which has been awarded this $1,057,268.80 task order under the NCI's "Cancer Prevention Agent Development Program 2012-2017" indefinite delivery contract.
The study involves a three-arm, Phase IIa randomized placebo-controlled trial to be conducted at Vanderbilt University Medical Center (VUMC), a major academic medical center, which has been awarded sub-contracts under this task order. The trial will enroll 90 colorectal adenoma patients, with two treatment arms and one placebo arm, to evaluate the effects of daily aspirin versus an intermittent aspirin dosing regimen. This award does not have any set-aside designations.
Quick answers
Who was awarded contract HHSN26100009?
HHSN26100009 was awarded to Northwestern University by National Cancer Institute (National Institutes of Health) on September 1, 2016.
How much is contract HHSN26100009 worth?
The government has obligated $1,057,269 on HHSN26100009.
Is contract HHSN26100009 an order under another contract?
Yes. HHSN26100009 is a delivery order under HHSN261201200035I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100009 competed?
The extent of competition for HHSN26100009 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award